Editorials

Humana's reported profit fell sharply across the first three quarters of 2026. Operating income went from $1.754 billion in the first quarter to $1.360 billion in the second and $75 million in the third, according to the company's quarterly filings. Most of the decline arrived in the most recent quarter. The line items in the company's 10-Q for the quarter ended September 30, 2026, filed November 6, 2026, show where the compression sits and which lines softened it.

Operating income fell by $394 million from the first quarter to the second, and by a further $1.285 billion in the third. The third-quarter drop accounts for roughly three-quarters of the $1.679 billion decline across the year. Net income followed the same path, falling from $1.186 billion to $694 million and then to $162 million. Diluted EPS dropped from $9.83 to $5.73 and then to $1.33. The diluted share count rose only modestly, from about 120.7 million shares in the first quarter to about 121.8 million in the third, so the per-share decline reflects earnings rather than dilution.

The income statement lines explain the third-quarter step-down. Between the second and third quarters, total revenues rose by about $288 million, but policyholder benefits and claims rose by about $954 million, while premiums earned, net, dipped by about $133 million. Selling, general and administrative expense rose about $620 million. Benefits growing faster than revenue, combined with a higher SG&A base, is the arithmetic behind the third-quarter result.

The gap between premiums earned and policyholder benefits, a rough gauge of how much premium revenue remains after medical costs, narrowed from about $4.0 billion in the first quarter to about $3.5 billion in the second and about $2.4 billion in the third. Other operating costs in the reconciliation between revenue and operating income stayed roughly flat across the three quarters, so the swing is concentrated in benefits and SG&A rather than in a broad rise in overhead.

Income tax expense fell from $395 million in the first quarter to $238 million in the second and $40 million in the third. Pre-tax income fell far more steeply than net income in dollar terms: pre-tax income dropped by about $1.38 billion from the first quarter to the third, while net income dropped by about $1.02 billion. The lower tax charge absorbed roughly $355 million of that pre-tax decline. Because a smaller tax bill is not an operating improvement, the third-quarter net income figure of $162 million should be read with the $40 million tax charge in view.

Net investment income was $262 million in the first quarter, $253 million in the second and $329 million in the third. The third-quarter increase of about $76 million was the largest sequential move in the series, but it covers only a small fraction of the roughly $1.29 billion operating income decline in that quarter. In its 2025 annual MD&A, the company said investment income fell 17.9% for the year, and full-year 2025 net investment income was $1.006 billion, against $1.226 billion in 2024. The 2026 quarters therefore show a modest recovery from a lower base rather than a line capable of offsetting the insurance and services results.

Pre-tax income in the third quarter ($216 million) was well above operating income ($75 million). The difference comes from two lines below operating income: interest expense of $217 million, which rose from $193 million in the first quarter and $197 million in the second, and an other nonoperating income and expense line that swung to a positive $358 million from negative $211 million in the second quarter. That line carried much of the third-quarter pre-tax result. The company's filings in the indexed data do not give enough detail to identify its components, so readers who want to know whether that gain recurs should consult the composition disclosures in the 10-Q itself.

The 2026 pattern follows a difficult 2025. In its 2025 annual MD&A, the company attributed results to premium growth, a higher benefit ratio of 90.2% (up 40 basis points), $449 million of value-creation charges, $253 million of impairments and a $67 million loss on sale of business, partly offset by $1.0 billion of favorable prior-period reserve development. Individual Medicare Advantage membership fell 7.3% in that year. Operating income for the full year 2025 was $2.704 billion, and the fourth quarter of 2025 recorded an operating loss of $808 million. The first quarter of 2026 operating income of $1.754 billion was below the $2.014 billion reported for the first quarter of 2025, and the third quarter of 2026 was well below the $400 million reported for the third quarter of 2025 only in the sense that the comparison is against a higher base in the prior year's second quarter; the quarterly series is volatile.

Three questions follow directly from the numbers. First, what drove the step-up in policyholder benefits between the second and third quarters, and how much of it reflects membership mix versus cost trends? Second, what is in the other nonoperating income line that turned positive in the third quarter, and does it repeat? Third, how much of the $620 million rise in SG&A reflects the value-creation and integration activity the company has described in prior filings? The quarterly statements answer the arithmetic. The segment and footnote disclosures in the 10-Q are where the causes would have to be traced, and readers should work through those before drawing conclusions about the run-rate of earnings.